PMID- 34896310 OWN - NLM STAT- MEDLINE DCOM- 20220316 LR - 20220316 IS - 1534-4436 (Electronic) IS - 1081-1206 (Linking) VI - 128 IP - 3 DP - 2022 Mar TI - Optimizing tools for evaluating challenge outcomes in children with cashew nut allergy. PG - 270-278 LID - S1081-1206(21)01302-8 [pii] LID - 10.1016/j.anai.2021.12.006 [doi] AB - BACKGROUND: The incidence of cashew nut anaphylaxis is increasing and there is a need for accurate diagnostic tests. Age-specific cutoffs in children are lacking. Changes in serum tryptase levels are not well documented in pediatric food allergy, except in anaphylaxis. OBJECTIVE: To evaluate the ability of various tests to diagnose cashew nut allergy and to predict reaction severity. We also investigated changes in tryptase and their correlation to reaction severity. METHODS: We performed an open cashew nut challenge on 106 children (aged 1-16 years), who were sensitized to cashew nut with either previous allergic reaction to cashew nut or no known exposure. We analyzed the accuracy of Ana o 3 immunoglobulin E (IgE), cashew nut IgE, skin prick test, basophil activation test (BAT), and combinations thereof to diagnose cashew nut allergy and to predict reaction severity. Tryptase level was measured at the baseline and during an allergic reaction. RESULTS: A total of 72 children had positive challenge outcomes. Ana o 3 IgE seemed to be the best single test to diagnose cashew allergy, with a 0.97 kU/L cutoff exhibiting 94.1% specificity and 61.1% sensitivity. Though BAT values of at least 22.8% best predicted reaction severity, with 91.7% specificity and 60.7% sensitivity, the cutoffs were age-specific. Tryptase levels increased substantially 1 to 2 hours after the first allergic symptoms compared with baseline. CONCLUSION: Ana o 3 IgE seems to be the best diagnostic test in pediatric cashew nut allergy, and test combinations do not seem to improve the diagnostics. Cutoffs are age-specific. BAT is promising in predicting reaction severity. Tryptase levels should be measured 1 to 2 hours after initiation of an allergic reaction. CI - Copyright (c) 2021 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. FAU - Rontynen, Petteri AU - Rontynen P AD - Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: petteri.rontynen@hus.fi. FAU - Kukkonen, Kaarina AU - Kukkonen K AD - Children's Hospital and Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. FAU - Savinko, Terhi AU - Savinko T AD - Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. FAU - Makela, Mika J AU - Makela MJ AD - Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211208 PL - United States TA - Ann Allergy Asthma Immunol JT - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology JID - 9503580 RN - 0 (Allergens) RN - 37341-29-0 (Immunoglobulin E) SB - IM MH - Adolescent MH - Allergens MH - *Anacardium MH - Child MH - Child, Preschool MH - Humans MH - Immunoglobulin E MH - Infant MH - *Nut Hypersensitivity/diagnosis MH - Skin Tests EDAT- 2021/12/14 06:00 MHDA- 2022/03/17 06:00 CRDT- 2021/12/13 12:18 PHST- 2021/06/03 00:00 [received] PHST- 2021/11/02 00:00 [revised] PHST- 2021/12/01 00:00 [accepted] PHST- 2021/12/14 06:00 [pubmed] PHST- 2022/03/17 06:00 [medline] PHST- 2021/12/13 12:18 [entrez] AID - S1081-1206(21)01302-8 [pii] AID - 10.1016/j.anai.2021.12.006 [doi] PST - ppublish SO - Ann Allergy Asthma Immunol. 2022 Mar;128(3):270-278. doi: 10.1016/j.anai.2021.12.006. Epub 2021 Dec 8.